News & Updates
Filter by Specialty:
Show Multimedia Only

PORTEC-3: Adjuvant chemoradiotherapy improves 10-year OS in high-risk endometrial cancer
15 Sep 2025
byKanas Chan
Adjuvant chemoradiotherapy (CRT) improves both 10-year overall survival (OS) and recurrence-free survival (RFS) in women with high-risk endometrial cancer vs pelvic radiotherapy alone, with the most clinically relevant benefit observed in p53 abnormal cancers, according to the 10-year analysis of the phase III PORTEC-3 trial.
PORTEC-3: Adjuvant chemoradiotherapy improves 10-year OS in high-risk endometrial cancer
15 Sep 2025
What’s hot at APS & MCV 2025?
15 Sep 2025
MIMS Doctor brings you extensive coverage of the Asia Pneumonia Summit & MasterClass in Vaccinology 2025, held recently in Taipei, Taiwan. Check out the latest updates on RSV, pneumococcal disease, new vaccines, plus thought-provoking insights from respiratory experts. [READ THE FULL REPORT]







